FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1967519489> ?p ?o ?g. }

• W1967519489 endingPage "344" @default.
• W1967519489 startingPage "343" @default.
• W1967519489 abstract "Relapse to drug-seeking after abstinence is the most challenging problem in treating drug addiction. Therefore, the demand for anti-relapse medications is high. Clinical trials have reported that modafinil, a wake-promoting agent used to treat sleep disorders such as narcolepsy, is effective in treating cocaine dependence. Although a weak stimulant, sites of action and behavioral effects of modafinil appear to be different from those of cocaine or amphetamine. Modafinil blunts the reinforcing as well as cardiovascular effects of cocaine. More importantly, modafinil decreases cocaine use and relapse rates in cocaine addicts (Dackis et al, 2005; Hart et al, 2008). Larger multi-center clinical trials of modafinil have found modestly positive outcomes (Anderson et al, 2009). In addition, modafinil showed promise in a small group of methamphetamine-dependent subjects and in pathological gamblers with high impulsivity. However, it appears that modafinil may only be effective in cocaine addicts without alcohol dependence (Anderson et al, 2009). Modafinil also is reported to increase negative affect and withdrawal symptoms associated with nicotine dependence. These findings indicate consideration of smoking and alcohol abuse in using modafinil as an anti-relapse medication.Despite clinical uses of modafinil, its mechanism(s) of action is still unclear. Using an animal model of relapse, we recently found that modafinil blocked reinstatement of an extinguished morphine conditioned place preference (CPP) in rats, extending the anti-relapse properties of modafinil to opiates (Tahsili-Fahadan et al, 2008). This anti-relapse effect of modafinil was blocked by administering an mGluR2/3 receptor antagonist, LY341495 (Figure 1), which is in line with previous findings, indicating the involvement of mGlu2/3 receptors in treatments for opiate and cocaine reinstatement in animal studies (Kalivas, 2009). This finding leads us to hypothesize that modafinil may block opiate relapse by stimulating mGlu2/3 receptors, effectively replacing the depleted tonic glutamate reservoir in the brain induced by chronic exposure to drugs of abuse, thereby preventing relapse to drug-seeking/taking (Kalivas, 2009).Figure 1mGlu2/3 receptor blockade prevents the anti-relapse effects of modafinil. Rats were trained for conditoned place preference (CPP) with morphine (8 mg/kg) in a six-session conditioning protocol over 3 consecutive days. Animals were then exposed ...In addition to this possible glutamate-mediated mechanism, modafinil is reported to affect other neurotransmitter systems such as catecholamines, serotonin, GABA, orexin, and histamine. The mild stimulant properties of modafinil may also be involved in its ability to reduce withdrawal symptoms of stimulant abuse. In a recent human PET study, modafinil was shown to block DA transporters and increase dopamine in the human brain including the nucleus accumbens (Volkow et al, 2009), in line with previous animal data. These and other findings highlight a potential for abuse of modafinil, although available data suggest a much lower potential for abuse and dependency than amphetamine-like stimulants (Myrick et al, 2004).Altogether, modafinil shows promise as an anti-relapse medication. Nonetheless, its abuse potential and exact mechanism of action warrants further clinical and preclinical investigations." @default.
• W1967519489 created "2016-06-24" @default.
• W1967519489 creator A5030113568 @default.
• W1967519489 creator A5057442519 @default.
• W1967519489 creator A5061094854 @default.
• W1967519489 date "2009-12-10" @default.
• W1967519489 modified "2023-09-27" @default.
• W1967519489 title "Modafinil: an anti-relapse medication" @default.
• W1967519489 cites W1966136869 @default.
• W1967519489 cites W1967074507 @default.
• W1967519489 cites W2021594631 @default.
• W1967519489 cites W2037263419 @default.
• W1967519489 cites W2055500305 @default.
• W1967519489 cites W2140991283 @default.
• W1967519489 doi "https://doi.org/10.1038/npp.2009.123" @default.
• W1967519489 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3055422" @default.
• W1967519489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20010710" @default.
• W1967519489 hasPublicationYear "2009" @default.
• W1967519489 type Work @default.
• W1967519489 sameAs 1967519489 @default.
• W1967519489 citedByCount "3" @default.
• W1967519489 countsByYear W19675194892014 @default.
• W1967519489 countsByYear W19675194892018 @default.
• W1967519489 crossrefType "journal-article" @default.
• W1967519489 hasAuthorship W1967519489A5030113568 @default.
• W1967519489 hasAuthorship W1967519489A5057442519 @default.
• W1967519489 hasAuthorship W1967519489A5061094854 @default.
• W1967519489 hasBestOaLocation W19675194891 @default.
• W1967519489 hasConcept C118552586 @default.
• W1967519489 hasConcept C15744967 @default.
• W1967519489 hasConcept C2780714222 @default.
• W1967519489 hasConcept C71924100 @default.
• W1967519489 hasConcept C98274493 @default.
• W1967519489 hasConceptScore W1967519489C118552586 @default.
• W1967519489 hasConceptScore W1967519489C15744967 @default.
• W1967519489 hasConceptScore W1967519489C2780714222 @default.
• W1967519489 hasConceptScore W1967519489C71924100 @default.
• W1967519489 hasConceptScore W1967519489C98274493 @default.
• W1967519489 hasIssue "1" @default.
• W1967519489 hasLocation W19675194891 @default.
• W1967519489 hasLocation W19675194892 @default.
• W1967519489 hasLocation W19675194893 @default.
• W1967519489 hasLocation W19675194894 @default.
• W1967519489 hasOpenAccess W1967519489 @default.
• W1967519489 hasPrimaryLocation W19675194891 @default.
• W1967519489 hasRelatedWork W1966747478 @default.
• W1967519489 hasRelatedWork W1994466998 @default.
• W1967519489 hasRelatedWork W2005320342 @default.
• W1967519489 hasRelatedWork W2006007764 @default.
• W1967519489 hasRelatedWork W2048727294 @default.
• W1967519489 hasRelatedWork W2070287162 @default.
• W1967519489 hasRelatedWork W2569917403 @default.
• W1967519489 hasRelatedWork W2748952813 @default.
• W1967519489 hasRelatedWork W2768810410 @default.
• W1967519489 hasRelatedWork W2899084033 @default.
• W1967519489 hasVolume "35" @default.
• W1967519489 isParatext "false" @default.
• W1967519489 isRetracted "false" @default.
• W1967519489 magId "1967519489" @default.
• W1967519489 workType "article" @default.